Third Rock Ventures

Reviewed Updated Apr 1, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Boston, MA
Founded 2007
Fund Size $3.8B total across six funds
Website https://www.thirdrockventures.com
Stage Focus
seed series-a
Sector Focus
biotech life-sciences therapeutics drug-discovery genomics precision-medicine gene-therapy oncology rare-disease neuroscience medical-devices diagnostics

Team

Robert Tepper Founding Partner
Kevin Starr Founding Partner
Mark Levin Founding Partner
Abbie Celniker Partner
Reid Huber Partner
Jeffrey Tong Partner
Cary Pfeffer Partner
David Kaufman Partner
Neil Exter Partner
Kevin Gillis Partner & COO

About

Third Rock Ventures is a healthcare venture capital firm founded in 2007, headquartered in Boston, Massachusetts, with an additional office in San Francisco 1. The firm was co-founded by Mark Levin, Kevin Starr, and Robert Tepper, all former executives at Millennium Pharmaceuticals 2. The idea for the firm originated at a Las Vegas casino in 2006, where the three lamented the dearth of funding for biotechnology startups working on big innovations 2.

Third Rock operates a distinctive company creation model: rather than investing in existing startups, the firm conceives and builds life science companies from scratch, often with partners serving as interim executives during the launch phase 1 3. The firm describes its process as “Discover. Launch. Build. Transform.” 1.

Third Rock raised its first fund of $378 million within 10 weeks of launching in 2007 2 4. The firm has since raised $3.8 billion across six funds 5:

Fund Year Size
Fund I 2007 $378M 4
Fund II 2010 $426M 6
Fund III 2013 $516M 7
Fund IV 2016 $616M 8
Fund V 2019 $770M 9
Fund VI 2022 $1.1B 5

As of early 2026, the firm has invested in 73 portfolio companies, with 25 products reaching the market 1. Nineteen portfolio companies have gone public, and 23 have been acquired 10. The firm’s investor base includes university endowments, family offices, foundations, and the Wellcome Trust, which has invested in all of Third Rock’s funds 9.

Third Rock topped STAT’s 2025 annual ranking of biotech venture capital firms, delivering the best returns among 22 prominent firms analyzed. For every dollar invested, the firm made a median $3.58 based on its first three funds (2007-2013 vintages) 11. Fund I generated a 25.7% internal rate of return, placing it in the top performance quartile 2.

Stated Thesis

Third Rock publicly describes its mission as translating scientific discoveries into breakthrough medicines to benefit patients 1. The firm states that it targets “disruptive areas of science and medicine” with significant unmet medical needs 1 3.

Robert Tepper has stated: “Our investment philosophy has always been shaped by the ongoing tremendous innovation in science and medicine. We aim to be both the preferred partner to scientific innovators from academia, and the preferred provider of innovative programs in important disease areas to address the bio-pharma industry’s pipeline needs” 8.

Kevin Starr described the firm’s founding motivation: “We came to the conclusion that the venture capital model was broken. A lot of that was because venture lost courage. They lost the courage for the big idea, the ‘change the world’-type vision” 2.

Reid Huber has said: “An important differentiator for Third Rock is the strength and maturity of our ideation ecosystem. Our discovery pipeline is as robust as it has ever been, and with our established and proven model for integrating deep scientific and medical expertise with operational and business acumen, we are uniquely positioned to advance these innovations to patients” 5 12.

The firm emphasizes that it creates companies rather than simply investing in them. Mark Levin has stated: “Individual genius is great, but drug development goes well beyond individual genius” 2. Robert Tepper has said: “We’re a company that builds companies” 2.

Inferred Thesis

Based on 73 verified portfolio companies from the firm’s website 1, Third Rock’s actual investment behavior closely aligns with its stated thesis, though with notable patterns:

Sector concentration: The overwhelming majority of Third Rock’s portfolio is in therapeutics and drug discovery. Based on the 73 companies listed on the firm’s portfolio page: approximately 55 of 73 (75%) are biopharmaceutical/therapeutics companies developing novel drugs. The remainder spans diagnostics (Foundation Medicine, Thrive Earlier Detection, NinePoint Medical), medical devices (Element Science, Corvia Medical, Kibur Medical), gene therapy (bluebird bio, Editas Medicine, Voyager Therapeutics), and computational biology/platform companies (Insitro, Relay Therapeutics, Warp Drive Bio). Sample size: 73 companies 1.

Therapeutic area breakdown: Among the ~55 therapeutics companies: oncology represents the largest focus area with approximately 18 of 55 (33%) including Agios, Blueprint Medicines, Jounce Therapeutics, Tango Therapeutics, CytomX, Neon Therapeutics, Flare Therapeutics, Faze Medicines, MOMA Therapeutics, Synnovation Therapeutics, and others. Neuroscience/CNS is the second-largest area with approximately 8 of 55 (15%) including Sage Therapeutics, Seaport Therapeutics, Syremis Therapeutics, Trace Neuroscience, Rapport Therapeutics, Decibel Therapeutics, and Afferent Pharmaceuticals. Rare/genetic disease represents approximately 8 of 55 (15%) including Global Blood Therapeutics, Rhythm Pharmaceuticals, Fulcrum Therapeutics, Allena Pharmaceuticals, and Edimer Pharmaceuticals. Immunology/autoimmune accounts for approximately 7 of 55 (13%) including Rheos Medicines, Abata Therapeutics, Merida Biosciences, Clasp Therapeutics, and Candid Therapeutics. Cardiovascular is approximately 4 of 55 (7%) including MyoKardia, Corvia Medical, and Element Science 1.

Stage focus: Third Rock operates almost exclusively at the company creation and Series A stage. The firm typically provides initial Series A financing when it launches a company, with check sizes ranging from $25M to $165M. Recent examples include Syremis Therapeutics ($165M Series A, 2025) 13, Seaport Therapeutics ($100M Series A, 2024) 14, Relay Therapeutics ($57M Series A, 2016) 15, and Tango Therapeutics ($55M Series A) 16. The firm also provides follow-on capital for subsequent rounds 5.

Geographic concentration: The vast majority of portfolio companies are based in the Boston/Cambridge, Massachusetts area, consistent with the firm’s headquarters and the region’s concentration of academic medical research institutions. A smaller number are based in the San Francisco Bay Area 1 10.

Company creation model: Unlike traditional venture firms, Third Rock primarily builds companies from scratch rather than investing in existing startups. Partners serve as interim CEOs and take hands-on executive roles during the launch phase, then transition to board roles as permanent management teams are hired 3. Robert Tepper stated: “If we can hold on to those companies as the sole investor or the predominant investor, we think we can get much higher up on the value-creation curve” 9.

Co-investor patterns: Because of the company creation model, Third Rock often serves as the sole or predominant initial investor. In later rounds, frequent co-investors include ARCH Venture Partners (Seaport Therapeutics), Greylock Partners (Warp Drive Bio), Google Ventures (Foundation Medicine), and large pharmaceutical companies through strategic collaborations 14 15.

Notable gap: Despite being a healthcare-focused firm, Third Rock has minimal exposure to digital health, health IT, or healthcare services. The portfolio is almost entirely concentrated in therapeutics, diagnostics, and medical devices with a strong bias toward novel drug discovery.

Portfolio

The following table includes selected portfolio companies. This represents a substantial portion of the firm’s 73 total portfolio companies 1.

Company Stage Year Sector Status Source
Syremis Therapeutics Series A ($165M) 2025 Neuropsychiatry Active 13
Azalea Therapeutics Series A 2025 Oncology/Immunotherapy Active 1
Candid Therapeutics Series A 2025 Immunology Active 1
Seaport Therapeutics Series A ($100M) 2024 Neuropsychiatry Active 14
Clasp Therapeutics Series A ($150M) 2024 Immunology/Oncology Active 21
Synnovation Therapeutics Series A ($102M) 2024 Oncology Active 22
ArtBio Series A ($90M) 2023 Oncology/Radiopharmaceutical Active 23
Trace Neuroscience Series A ($101M) 2024 Neuroscience/ALS Active 24
Marea Therapeutics Series A+B ($190M) 2024 Cardiometabolic Active 25
Rapport Therapeutics Series A ($100M) 2023 Neuroscience Active 26
Terremoto Biosciences Series A ($75M) 2022 Drug Discovery Active 27
Septerna Series A ($100M) 2022 Drug Discovery/GPCR Public (IPO, Jan 2025) 28
Abata Therapeutics Series A ($95M) 2021 Immunology/Neuroinflammation Active 29
Asher Bio Series A ($55M) 2021 Immunology Active 30
Flare Therapeutics Series A ($82M) 2021 Oncology Active 31
Cargo Therapeutics Series A ($200M) 2023 Cell Therapy Public (IPO) 32
MOMA Therapeutics Series A 2020 Oncology Active 110
Faze Medicines Series A ($81M) 2020 Drug Discovery Shut down (2022) 33
Thrive Earlier Detection Series A 2019 Diagnostics/Oncology Acquired 9
Maze Therapeutics Series A ($191M) 2019 Genetic Disease Public (IPO, Jan 2025) 34
Insitro Series A 2018 Computational Biology Active 1
CASMA Therapeutics Series A ($58.5M) 2018 Autophagy Active 35
Cedilla Therapeutics Series A ($56M) 2018 Oncology Active 36
Rheos Medicines Series A ($60M) 2018 Immunology Acquired 37
Tango Therapeutics Series A ($55M) 2017 Oncology Public (IPO) 16
Relay Therapeutics Series A ($57M) 2016 Drug Discovery/Oncology Public (IPO) 15
Magenta Therapeutics Series A ($48.5M) 2016 Stem Cell Public (IPO) 38
Goldfinch Bio Series A ($55M) 2016 Kidney Disease Shut down 39
Pliant Therapeutics Series A ($45M) 2016 Fibrosis Public (IPO) 40
Fulcrum Therapeutics Series A ($55M) 2016 Genetic Disease Public (IPO) 41
Decibel Therapeutics Series A ($52M) 2015 Hearing Loss Acquired (Regeneron) 42
Neon Therapeutics Series A ($55M) 2015 Immuno-oncology Acquired 43
REVOLUTION Medicines Series A ($45M) 2015 Oncology Public (IPO) 44
Nurix Therapeutics Series B ($25M) 2014 Drug Discovery Public (IPO) 45
Voyager Therapeutics Series A ($45M) 2014 Gene Therapy/Neurology Public (IPO) 46
Jounce Therapeutics Series A ($47M) 2013 Immuno-oncology Public (IPO) 47
Editas Medicine Series A 2013 Gene Editing Public (IPO) 1
Blueprint Medicines Series A 2011 Oncology Public (IPO) 7
MyoKardia Series A 2012 Cardiovascular Acquired (BMS, $13.1B, 2020) 17
Global Blood Therapeutics Series A ($40.7M) 2012 Hematology Public (IPO); Acquired (Pfizer) 48
Warp Drive Bio Series A 2012 Drug Discovery Acquired (Revolution Medicines, 2018) 3
Allena Pharmaceuticals Series A ($15M) 2011 Kidney/Metabolic Public (IPO) 49
Element Science Series A 2011 Medical Devices Active 1
Ember Therapeutics Series A 2011 Metabolic Disease Shut down 50
Lotus Tissue Repair Series A ($26M) 2011 Dermatology Acquired (Shire, 2013) 51
SAGE Therapeutics Series A 2011 Neuroscience/CNS Public (IPO) 18
Sesen Bio (Eleven Bio) Series A 2011 Oncology Public (IPO) 1
CytomX Therapeutics Series A 2010 Oncology Public (IPO) 7
Kala Bio Series A 2009 Ophthalmology Public (IPO) 7
Constellation Pharmaceuticals Series A ($32M) 2008 Oncology/Epigenetics Public (IPO); Acquired 52
Agios Pharmaceuticals Series A 2008 Oncology/Metabolism Public (IPO) 2
Alnara Pharmaceuticals Series A 2008 GI Disease Acquired (Eli Lilly, 2010) 7
Zafgen Series A 2008 Metabolic Disease Public (IPO) 7
bluebird bio Series B 2010 Gene Therapy Public (IPO) 7
Rhythm Pharmaceuticals Series A 2012 Rare Disease Public (IPO) 7
Foundation Medicine Series A 2008 Genomic Diagnostics Public (IPO); Acquired (Roche, $5B) 2

In Their Own Words

“We came to the conclusion that the venture capital model was broken. A lot of that was because venture lost courage. They lost the courage for the big idea, the ‘change the world’-type vision.” — Kevin Starr, Fortune, February 2015 2

“The patients are getting screwed. We need to do something.” — Kevin Starr, Fortune, February 2015 2

“For us, these aren’t investments. It’s validation that our babies are coming into adolescence.” — Kevin Starr, on portfolio company IPOs, Fortune, February 2015 2

“Individual genius is great, but drug development goes well beyond individual genius.” — Mark Levin, Fortune, February 2015 2

“We’re a company that builds companies.” — Robert Tepper, Fortune, February 2015 2

“People are the single biggest asset at Third Rock.” — Robert Tepper, BioSpace, March 2013 7

“Our approach has always been to seek out and explore unique collaborative models that are aligned with our mission and vision.” — Mark Levin, BioSpace, March 2013 7

“If we can hold on to those companies as the sole investor or the predominant investor, we think we can get much higher up on the value-creation curve.” — Robert Tepper, BioSpace, June 2019 9

“We believe that people are our greatest asset, and we invest significant effort and resources to ensure we hire the best people at Third Rock and across the portfolio.” — Abbie Celniker, Labiotech.eu, June 2022 12

“Over the course of our 15-year history, our focus on creating companies aimed at improving the lives of patients has not wavered.” — Kevin Gillis, Labiotech.eu, June 2022 12

“It’s been a challenging environment in the last few months. But on the company creation side … we just have a very loyal base of [limited partners].” — Jeffrey Tong, BioSpace, June 2022 5

“Trying to create a medicine is a wickedly tough thing to do. It takes a village, it takes experience.” — Alexis Borisy (former Partner), Harvard Stem Cell Institute 19

What Founders Say

“They’re willing to think big.” — Jeff Jonas, M.D., CEO of Sage Therapeutics, speaking about Third Rock, Fierce Biotech 18

“They’re incredibly unique in sharing their passion and vision. They’re willing to consider very important opportunities that come with high hurdles. They believe that, with a little more work, the right funding, and a little more patience, you can overcome those hurdles.” — Michael Pellini, M.D., former CEO of Foundation Medicine 20

“It was group genius.” — Alexis Borisy, co-founder and first CEO of Foundation Medicine, describing the collaborative process with Third Rock, Fortune, February 2015 2

“They’re one of the few firms I’ve seen in 30 years that have reinvented the model of venture capital.” — Bill Helman, Greylock Partners, Fortune, February 2015 2

Note: The Bill Helman quote is from a fellow venture capitalist rather than a portfolio founder. Third Rock’s company creation model means many “founders” are Third Rock partners themselves, making traditional founder testimonials less applicable. The Pellini and Jonas quotes represent the perspective of recruited CEOs who led Third Rock-created companies.

Sources

  1. Third Rock Ventures website, homepage and portfolio page, accessed April 2026. https://www.thirdrockventures.com/ and https://www.thirdrockventures.com/portfolio↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

  2. Fortune, “Third Rock Ventures: Giving birth to a new generation of biotechs,” February 2015. https://fortune.com/2015/02/19/third-rock-ventures-giving-birth-to-a-new-generation-of-biotechs/↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

  3. Third Rock Ventures website, “Approach” page, accessed April 2026. https://www.thirdrockventures.com/approach↩↩↩↩

  4. Fierce Biotech, “PRESS RELEASE: Third Rock Ventures Debuts with $378 Million Fund in Life Sciences,” 2007. https://www.fiercebiotech.com/biotech/press-release-third-rock-ventures-debuts-378-million-fund-life-sciences↩↩

  5. BioSpace, “In Tough Biotech Market, Third Rock Raises New $1.1B Fund,” June 2022. https://www.biospace.com/in-tough-biotech-market-third-rock-raises-new-1-1-billion-fund↩↩↩↩↩

  6. Fierce Biotech, “Third Rock Ventures Raises $426 Million Fund II,” September 2010. https://www.fiercebiotech.com/biotech/third-rock-ventures-raises-426-million-fund-ii↩

  7. BioSpace, “Third Rock Ventures Stocks Up With $516 Million New Fund, Looks to Start 16 Companies,” March 2013. https://www.biospace.com/third-rock-ventures-stocks-up-with-516-million-new-fund-looks-to-start-16-companies↩↩↩↩↩↩↩↩↩↩

  8. Business Wire, “Third Rock Ventures Raises $616 Million Fund IV,” October 2016. https://www.businesswire.com/news/home/20161031005378/en/Rock-Ventures-Raises-616-Million-Fund-IV↩↩

  9. BioSpace, “Third Rock Venture to Seed Life Science Companies with $770 Million Fund,” June 2019. https://www.biospace.com/article/third-rock-ventures-fund-v-raises-770-million/↩↩↩↩↩

  10. Tracxn, “Third Rock Ventures - 2026 Investor Profile,” accessed April 2026. https://tracxn.com/d/venture-capital/third-rock-ventures/__g9e1cRQjBZe-J6re4KmJ8JyKq3z3JS0M4qFFHbhzvPY↩↩↩

  11. STAT News, “Third Rock Ventures tops STAT’s 2025 ranking of biotech VC firms,” August 2025. https://www.statnews.com/2025/08/27/third-rock-ventures-tops-stat-annual-biotech-vc-rankings/↩

  12. Labiotech.eu, “Biotech companies to benefit from Third Rock Ventures $1.1B fund,” June 2022. https://www.labiotech.eu/trends-news/third-rock-fund/↩↩↩

  13. Goodwin Law, “Goodwin Advises Third Rock Ventures, Co-Lead Investor on the $165 Million Series A Financing to Launch Syremis Therapeutics,” December 2025. https://www.goodwinlaw.com/en/news-and-events/news/2025/12/announcements-lifesciences-goodwin-advises-third-rock-ventures↩↩

  14. Seaport Therapeutics press release, “Seaport Therapeutics Launches with $100 Million Oversubscribed Series A,” April 2024. https://seaporttx.com/wp-content/uploads/2024/04/20240409_press_release.pdf↩↩↩

  15. Relay Therapeutics press release, “Third Rock Ventures Launches Relay Therapeutics with $57 Million Series A Financing,” September 2016. https://ir.relaytx.com/news-releases/news-release-details/third-rock-ventures-launches-relay-therapeutics-57-million↩↩↩

  16. Tango Therapeutics press release, “Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment.” https://ir.tangotx.com/news-releases/news-release-details/third-rock-ventures-launches-tango-therapeutics-55-million↩↩

  17. Bristol Myers Squibb press release, “Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash,” October 2020. https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash/default.aspx↩

  18. Fierce Biotech, “Third Rock startup Sage banks $20M as it ‘thinks big’ about CNS drugs.” https://www.fiercebiotech.com/r-d/third-rock-startup-sage-banks-20m-as-it-thinks-big-about-cns-drugs↩↩

  19. Harvard Stem Cell Institute, “Alexis Borisy, Partner at Third Rock Ventures,” accessed April 2026. https://www.hsci.harvard.edu/resource/alexis-borisy-partner-third-rock-ventures↩

  20. Excedr, “Who Is Third Rock Ventures? An Overview,” accessed April 2026. https://www.excedr.com/blog/venture-capital-third-rock-ventures↩

  21. Fierce Biotech, “Third Rock, Novo Holdings-backed Clasp Tx hooks $150M series A for next-gen cancer treatments,” March 2024. https://www.fiercebiotech.com/biotech/clasp-tx-hooks-150m-series-next-gen-cancer-treatments↩

  22. BioSpace, “Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline,” January 2024. https://www.biospace.com/synnovation-therapeutics-launches-with-102-million-to-advance-clinical-stage-pipeline-of-precision-therapies-targeting-highly-validated-disease-pathways↩

  23. PR Newswire, “ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing,” December 2023. https://www.prnewswire.com/news-releases/artbio-raises-oversubscribed-and-upsized-90-million-series-a-financing-to-progress-pipeline-and-isotope-technology-development-for-new-class-of-alpha-radioligand-therapies-302008226.html↩

  24. BusinessWire, “Trace Neuroscience Launches With $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases,” November 2024. https://www.businesswire.com/news/home/20241112074588/en/Trace-Neuroscience-Launches-With-%24101-Million-Series-A-Financing-to-Expand-Genomic-Medicine-for-Neurodegenerative-Diseases↩

  25. BusinessWire, “Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases,” June 2024. https://www.businesswire.com/news/home/20240617273647/en/Marea-Therapeutics-Launches-with-%24190-Million-to-Accelerate-a-New-Generation-of-Medicines-for-Cardiometabolic-Diseases↩

  26. BusinessWire, “Rapport Therapeutics Launches with $100 Million,” March 2023. https://www.businesswire.com/news/home/20230307005230/en/Rapport-Therapeutics-Launches-with-100-Million-to-Transform-the-Treatment-of-Neurological-Disease-through-the-Discovery-and-Development-of-Precision-Therapies↩

  27. BusinessWire, “Terremoto Biosciences Launches With $75 Million Series A Financing,” May 2022. https://www.businesswire.com/news/home/20220525005250/en/Terremoto-Biosciences-Launches-With-$75-Million-Series-A-Financing-and-Mission-to-Discover-and-Develop-Groundbreaking-Covalent-Medicines↩

  28. Septerna press release, “Septerna Launches with $100 Million Series A Financing,” January 2022. https://ir.septerna.com/news-releases/news-release-details/septerna-launches-100-million-series-financing-expand-frontier↩

  29. BusinessWire, “Abata Therapeutics Launches to Usher in New Era of Cell Therapy Using Targeted Regulatory T Cells,” June 2021. https://www.businesswire.com/news/home/20210623005274/en/Abata-Therapeutics-Launches-to-Usher-in-New-Era-of-Cell-Therapy-Using-Targeted-Regulatory-T-Cells-to-Treat-Serious-Autoimmune-and-Inflammatory-Diseases↩

  30. BusinessWire, “Asher Bio Launches with $55 Million Series A Financing Led by Third Rock Ventures,” March 2021. https://www.businesswire.com/news/home/20210323005426/en/Asher-Bio-Launches-with-%2455-Million-Series-A-Financing-Led-by-Third-Rock-Ventures-to-Discover-and-Develop-Highly-Specific-Immunotherapies-Using-a-Novel-Technology-Platform↩

  31. BusinessWire, “Flare Therapeutics Launches with $82 Million Series A Financing,” May 2021. https://www.businesswire.com/news/home/20210513005311/en/Flare-Therapeutics-Launches-with-%2482-Million-Series-A-Financing-to-Advance-Precision-Oncology-Pipeline-based-on-Novel-Drug-Discovery-Approach-for-Transcription-Factors↩

  32. GlobeNewsWire, “CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing,” March 2023. https://www.globenewswire.com/news-release/2023/03/01/2618358/0/en/CARGO-Therapeutics-Raises-200-Million-in-Oversubscribed-Upsized-Series-A-Financing-to-Advance-its-Pipeline-of-Next-Generation-CAR-T-Cell-Therapies.html↩

  33. BusinessWire, “Faze Medicines Launches With $81 Million Series A Financing,” December 2020. https://www.businesswire.com/news/home/20201210005178/en/Faze-Medicines-Launches-With-%2481-Million-Series-A-Financing-to-Leverage-New-Biology-of-Biomolecular-Condensates-to-Treat-Disease↩

  34. Maze Therapeutics press release, “Maze Therapeutics Launches with $191 Million,” February 2019. https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-launches-191-million-focus-translating-genetic↩

  35. CASMA Therapeutics press release, “Third Rock Ventures Launches Casma Therapeutics with $58.5 Million Investment,” May 2018. https://www.casmatx.com/2018/05/03/third-rock-ventures-launches-casma-therapeutics-with-58-5-million-investment-to-harness-the-cellular-process-of-autophagy-to-develop-breakthrough-therapies/↩

  36. BusinessWire, “Third Rock Ventures Launches Cedilla Therapeutics with $56 Million Investment,” April 2018. https://www.businesswire.com/news/home/20180424005295/en/Rock-Ventures-Launches-Cedilla-Therapeutics-56-Million↩

  37. BusinessWire, “Third Rock Ventures Launches Rheos Medicines with $60 Million in Series A Funding,” March 2018. https://www.businesswire.com/news/home/20180322005056/en/Rock-Ventures-Launches-Rheos-Medicines-60-Million↩

  38. BusinessWire, “Magenta Therapeutics Announces $48.5M Series A Financing,” November 2016. https://www.businesswire.com/news/home/20161116005422/en/Magenta-Therapeutics-Announces-48.5M-Series-A-Financing-to-Transform-Stem-Cell-Transplant-for-Immune-and-Blood-Diseases↩

  39. BusinessWire, “Third Rock Ventures Launches Goldfinch Bio with $55 Million Series A Investment,” December 2016. https://www.businesswire.com/news/home/20161214005249/en/Third-Rock-Ventures-Launches-Goldfinch-Bio-with-55-Million-Series-A-Investment↩

  40. Pliant Therapeutics press release, “Third Rock Ventures Launches Pliant Therapeutics with $45 Million Series A,” February 2016. https://ir.pliantrx.com/news-releases/news-release-details/third-rock-ventures-launches-pliant-therapeutics-45-million/↩

  41. Fulcrum Therapeutics press release, “Third Rock Ventures Launches Fulcrum Therapeutics with $55 Million Series A Investment,” July 2016. https://www.fulcrumtx.com/third-rock-ventures-launches-fulcrum-therapeutics-with-55-million-series-a-investment/↩

  42. BusinessWire, “Third Rock Ventures Launches Decibel Therapeutics with $52 Million Series A Financing,” October 2015. https://www.businesswire.com/news/home/20151015005193/en/Rock-Ventures-Launches-Decibel-Therapeutics-52-Million↩

  43. BusinessWire, “Neon Therapeutics Launches with $55 Million Series A to Develop Neoantigen-based Cancer Immunotherapies,” October 2015. https://www.businesswire.com/news/home/20151001005330/en/Neon-Therapeutics-Launches-55-Million-Series-Develop↩

  44. BusinessWire, “Third Rock Ventures Launches REVOLUTION Medicines with $45 Million Series A,” February 2015. https://www.businesswire.com/news/home/20150204005264/en/Rock-Ventures-Launches-REVOLUTION-Medicines-45-Million↩

  45. Fierce Biotech, “Third Rock Ventures and The Column Group Launch Nurix with $25.1 Million Financing,” May 2014. https://www.fiercebiotech.com/biotech/third-rock-ventures-and-column-group-launch-nurix-25-1-million-financing-to-target-key↩

  46. BusinessWire, “Third Rock Ventures Launches Voyager Therapeutics with $45 Million Series A,” February 2014. https://www.businesswire.com/news/home/20140212005145/en/Third-Rock-Ventures-Launches-Voyager-Therapeutics-with-45-Million-Series-A-to-Develop-Life-Changing-Gene-Therapies-for-CNS-Disorders↩

  47. BusinessWire, “Third Rock Ventures Launches Jounce Therapeutics with $47 Million Series A to Transform Cancer Treatment,” February 2013. https://www.businesswire.com/news/home/20130214005207/en/Rock-Ventures-Launches-Jounce-Therapeutics-47-Million↩

  48. BusinessWire, “Third Rock Ventures Launches Global Blood Therapeutics with $40.7 Million,” June 2012. https://www.businesswire.com/news/home/20120614005312/en/Third-Rock-Ventures-Launches-Global-Blood-Therapeutics-with-40.7-Million-to-Revolutionize-the-Treatment-of-Chronic-Blood-Based-Diseases↩

  49. Allena Pharmaceuticals press release, “Allena Pharmaceuticals Launches with $15 Million Series A Round,” November 2011. https://ir.allenapharma.com/news-releases/news-release-details/allena-pharmaceuticals-launches-15-million-series-round↩

  50. BusinessWire, “Third Rock Ventures Launches Ember Therapeutics to Address Critical Need for Novel Treatments for Metabolic Disease,” December 2011. https://www.businesswire.com/news/home/20111215005181/en/Rock-Ventures-Launches-Ember-Therapeutics-Address-Critical↩

  51. BusinessWire, “Lotus Tissue Repair, Inc. Secures $26 Million Series A Financing,” June 2011. https://www.businesswire.com/news/home/20110630005087/en/Lotus-Tissue-Repair-Inc.-Secures-26-Million-Series-A-Financing-to-Develop-First-in-Class-Protein-Replacement-Therapy-for-Dystrophic-Epidermolysis-Bullosa↩

  52. Fierce Biotech, “Constellation Pharmaceuticals Closes $32 Million in Series A Funding,” 2008. https://www.fiercebiotech.com/biotech/constellation-pharmaceuticals-closes-32-million-series-a-funding↩